Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Inhaled 5-methoxy-N,N-dimethyltryptamine

Supportive context associated with positive acute and enduring effects

Bibliographic Data

ID4695897
AuthorsNathan D Sepeda (Johns Hopkins University, corresponding author), John M Clifton, John Clifton (Johns Hopkins Medicine), Laura Y Doyle (Johns Hopkins University), Rafael Lancelotta, Rafaelle L Lancelotta (0000-0002-7789-3463, University of Wyoming), Roland R Griffiths (0000-0001-5185-7854, Johns Hopkins Medicine), A K Davis (0000-0003-4770-8893, The Ohio State University)
Year2020
Volume4
Issue2
Pages114-122
Publication date2020-06-01
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueJournal of Psychedelic Studies (JOURNAL)
Journal identifiersISSN: 2559-9283 • E-ISSN: 2559-9283
PublisherAkademiai Kiado Zrt (PUBLISHER)
DOI10.1556/2054.2019.033
OpenAlexW2998604208
LanguageEN
Citations received4
References cited33

Background and aims 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a potent, short-acting psychedelic that produces strong hallucinogenic effects. The association between the context (i.e., set and setting) of 5-MeO-DMT use and the acute and enduring effects of the substance is unknown. Therefore, this study examined these associations using secondary data from two cross-sectional survey studies. Methods The acute and enduring effects of inhaled synthetic 5-MeO-DMT were compared between individuals who used 5-MeO-DMT in a non-structured context (NSC; n = 216, female = 10%, Mage = 35.5, SD = 11.8) and those who used in a structured context (SC; n = 362, female = 45%, Mage = 47.7, SD = 13.3). Questionnaires were administered online and responses were anonymized for privacy purposes. Respondents were asked to retrospectively rate their first experience with synthesized 5-MeO-DMT on measures of mystical experience, challenging experience, and enduring effects. Results Both groups endorsed high ratings on the Mystical Experience Questionnaire; however, mean scores were significantly higher in the SC group compared to the NSC group. Similarly, the proportion of respondents who had a complete mystical experience was significantly larger in the SC group (83%) compared to the NSC group (54%). Ratings of enduring effects (i.e., meaningfulness, spirituality, and well-being) were also significantly higher, and the intensity of challenging experiences was significantly lower, in the SC group compared to the NSC group. Conclusions 5-MeO-DMT appears to occasion mystical-type experiences with enduring positive effects, which are more intense when 5-MeO-DMT is administered in a safe and supportive context. Future prospective experimental studies should examine the effects of 5-MeO-DMT and its interactive relationship with supportive contextual factors

Alternative medicine · Mysticism · Spirituality · Theology · Chemical synthesis and alkaloids · Clinical Psychology · Forensic Toxicology and Drug Analysis · Medicine · Psychedelics and Drug Studies · Psychology

  • Altered States of Consciousness During Ceremonial San Pedro Use

    Open Access•Arne Bohn, Michiel H H Kiggen et al.•International Journal for the…•2022

  • Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures

    Open Access•A K Davis, Christopher Timmermann et al.•Journal of Psychoactive Drugs•2023

  • A Scoping Review of Research in Naturalistic Studies with Psychedelics

    Open Access•Laura C Carvalho, Jorge Encantado et al.•Journal of Psychoactive Drugs•2025

  • Predictors and potentiators of psychedelic-occasioned mystical experiences

    Open Access•Gandy•Journal of Psychedelic Studies•2022

  • Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer

    Open Access•Roland R Griffiths, Matthew W Johnson et al.•Journal of Psychopharmacology•2016

  • Survey study of challenging experiences after ingesting psilocybin mushrooms

    Open Access•Theresa M Carbonaro, Matthew P Bradstreet et al.•Journal of Psychopharmacology•2016

  • Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

    Open Access•Frederick S Barrett, Matthew W Johnson et al.•Journal of Psychopharmacology•2015

  • Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction

    Albert Garcia-Romeu, Albert Garcia‐Romeu et al.•Current Drug Abuse Reviewse•2015

  • Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

    Open Access•Robin Carhart‐Harris, Robin L Carhart-Harris et al.•Proceedings of the National…•2012

  • Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

    Open Access•Roland R Griffiths, William A Richards et al.•Psychopharmacology•2006

  • Human hallucinogen research

    Open Access•MW Johnson, WA Richards et al.•Journal of Psychopharmacology•2008

  • Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

    Charles S Grob, Alicia Danforth et al.•Archives of General Psychiatry•2011

  • Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors

    Open Access•Roland R Griffiths, Matthew W Johnson et al.•Journal of Psychopharmacology•2018

  • Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer

    Open Access•Stephen Ro, Stephen Ross et al.•Journal of Psychopharmacology•2016

  • Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

    Open Access•RR Griffiths, R R Griffiths et al.•Journal of Psychopharmacology•2008

  • Survey of subjective "God encounter experiences"

    Open Access•Roland R Griffiths, Ethan S Hurwitz et al.•PLoS ONE•2019

  • The Challenging Experience Questionnaire

    Open Access•Frederick S Barrett, Matthew P Bradstreet et al.•Journal of Psychopharmacology•2016

  • Psilocybin with psychological support for treatment-resistant depression

    Open Access•Robin L Carhart-Harris, Mark Bolstridge et al.•The Lancet Psychiatry•2016

  • Psychedelics

    Open Access•David E Nichols•Pharmacological Reviews•2016

  • Psilocybin occasioned mystical-type experiences

    Open Access•Roland R Griffiths, Matthew W Johnson et al.•Psychopharmacology•2011

  • Über Die Synthese Des Bufotenin-Methyl-Äthers (5-Methoxy-N-Dimethyl-Tryptamin) Und Bufotenins (Synthesen in Der Indol-Gruppe. Xv)

    Open Access•Toshio Hoshino, Kenya Shimodaira•Bulletin of the Chemical Society…•1936

  • Implications of LSD and experimental mysticism

    Open Access•Walter N Pahnke, William A Richards•Journal of Religion and Health•1966

  • Bufo alvarius

    Open Access•Andrew Weil, Andrew T Weil et al.•Journal of Ethnopharmacology•1994

  • Pharmepéna-Psychonautics

    Jonathan Ott•Journal of Psychoactive Drugs•2001

  • Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users

    Rafaelle L Lancelotta, Rafael L Lancelotta et al.•Journal of Psychoactive Drugs•2020

  • Bufo Toads and Bufotenine

    Thomas Lyttle, D Goldstein et al.•Journal of Psychoactive Drugs•1996

  • Factor Analysis of the Mystical Experience Questionnaire

    Open Access•Katherine A Maclean, Jeannie‐marie S Leoutsakos et al.•Journal for the Scientific Study…•2012

Unique citing works4
Citations per year1
Citation span2022 - 2025 (4)
Citation velocityrecent
Highly citedNo
Citation typesNeutral: 4

Tools

Open DOISci-HubOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae